RTW Investments, LP and its Managing Partner Roderick Wong, M.D. filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 8,535,153 shares of Pyxis Oncology, Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: RTW Investments, LP and Roderick Wong each reported beneficial ownership of 8,535,153 shares of Pyxis Oncology common stock.
- Percent of class: The filing reports each reporting person holds 9.9% (listed as 9.99% in Item 4) of Pyxis Oncology's outstanding shares.
- Warrant cap: The share total assumes exercise of warrants to purchase 2,028,924 shares, the maximum allowed given a contractual 9.99% ownership cap.
- Shares outstanding basis: Percentages are calculated on 83,408,050 shares outstanding as of August 19, 2026, as reported in the company's prospectus dated August 28, 2026.
- Voting and dispositive power: Both reporting persons report zero sole voting or dispositive power; all 8,535,153 shares carry shared voting and shared dispositive power.
- RTW Master Fund Ltd. identified: According to the filing, RTW Master Fund Ltd., an RTW Fund, has the right to receive dividends or proceeds from the sale of more than 5% of the shares reported.
RTW Investments and Roderick Wong Disclose Shared Stake via RTW Funds
According to the Schedule 13G filed on November 16, 2026, RTW Investments, LP, a Delaware limited partnership serving as investment adviser to certain funds referred to as the "RTW Funds," and Roderick Wong, M.D., the Managing Partner and Chief Investment Officer of RTW Investments, jointly reported a beneficial ownership position in Pyxis Oncology, Inc. The event triggering the filing occurred on September 30, 2026. The shares are directly held by the RTW Funds, with RTW Investments acting in its capacity as investment adviser.
The filing discloses that the 8,535,153 shares reported include the assumed exercise of warrants to purchase 2,028,924 shares. The filing states that "pursuant to the terms of the Warrants, the Reporting Persons cannot exercise any of the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Shares." Both RTW Investments and Dr. Wong report zero sole voting power and zero sole dispositive power, with all reported shares carrying shared voting and shared dispositive power between them.
The filing further notes that the RTW Funds have the right to receive, or the power to direct the receipt of, dividends from or proceeds from the sale of the reported shares, and that RTW Master Fund Ltd. specifically has such rights with respect to more than 5% of the shares. The reporting persons certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." Business addresses for both reporting persons are listed as 40 10th Avenue, Floor 7, New York, New York 10014.
What Was Disclosed
RTW Investments, LP and Roderick Wong, M.D. filed a Schedule 13G reporting shared beneficial ownership of 8,535,153 shares, or approximately 9.9% to 9.99%, of Pyxis Oncology, Inc. common stock, triggered by an event on September 30, 2026.




Please wait processing your request...